It was originally developed by Eli Lilly as a research molecule and is widely characterized in the literature as a unitary triple receptor agonist with affinity for the glucagon-like peptide-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR)
Early clinical trials suggest it might help people lose even more weight than current options, though its still being tested and isnt yet available to the public
When in doubt, replace the vial
This happens because your body holds onto extra water, which can be influenced by things like eating too much salt, feeling stressed, or taking certain medications
This is consistent with glucagon receptor activation, which has known cardiovascular effects
Our guide to getting the Wegovy pill on the NHS explains this in more detail